

In accordance with 37 C.F.R. § 1.121(c) (3), please substitute for pending claims 3 and 4 with the following clean version of the claims. The changes to these claims are shown explicitly in the attached "Marked Up Version of Claims."

Sub D1
16. (Amended) A pharmaceutical composition comprising at least one fusion protein from at least one L1 protein of one or more papillomaviruses and at least one C-terminally deleted E7 protein, wherein about 38 to about 43 amino acids are deleted, of one or more papillomaviruses, wherein the fusion protein contains no papillomavirus-unspecific epitopes and wherein the pharmaceutical composition is capable of preventing or treating human papillomavirus (HPV)-specific tumour.

17. (Amended) The pharmaceutical composition according to claim 16, wherein the tumour is a carcinoma of the larynx, cervix, penis, vulva or anus.

C
18. (Amended) The pharmaceutical composition according to claim 16, wherein the pharmaceutical composition contains no adjuvant.

Sub D2
19. (Amended) The pharmaceutical composition according to claim 16, wherein the pharmaceutical composition comprises suitable additives and/or excipients.

20. (Amended) The pharmaceutical composition according to claim 19, wherein the additive or excipient is about 0.3 to about 4 M of a salt having a pH of about 7.3 to about 7.45.

21. (Amended) The pharmaceutical composition according to claim 20, wherein the salt is an alkali metal or alkaline earth metal salt.

22. (Amended) The pharmaceutical composition according to claim 20, wherein the pH is adjusted using a buffer.

23. (Amended) The pharmaceutical composition according to claim 16, wherein the L1 protein is a deleted L1 protein.

24. (Amended) The pharmaceutical composition according to claim 23, wherein the L1 protein is a C-terminally deleted L1 protein.

25. (Amended) The pharmaceutical composition according to claim 23, wherein up to about 35 amino acids are deleted from the L1 protein.

29. (Amended) The pharmaceutical composition according to claim 16, wherein font fusion protein is present in the form of a capsid and/or capsomer.

30. (Amended) The pharmaceutical composition according to claim 16, wherein the HPV is selected from HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-42, HPV-45, HPV-52 and/or HPV-58.

31. (Amended) The pharmaceutical composition according to claim 30 in the form of a combination vaccine, wherein the papillomaviruses are selected from HPV-16 and HPV-18 or HPV-18, HPV-31, HPV-45 and HPV-58 or HPV-6 and HPV-11.

32. (Amended) The pharmaceutical composition according to claim 20, wherein the additive or excipient is 0.4 to about 3 M of a salt having a pH of about 7.3 to about 7.45.

33. (Amended) The pharmaceutical composition according to claim 20, wherein the additive or excipient is 0.5 to about 2 M of a salt having a pH of about 7.3 to about 7.45.

34. (Amended) The pharmaceutical composition according to claim 20, wherein the additive or excipient is 1 to about 2 M of a salt having a pH of about 7.3 to about 7.45.

35. (Amended) The pharmaceutical composition according to claim 20, wherein the salt has a pH of 74.

36. (Amended) The pharmaceutical composition according to claim 21, wherein the salt is a halide or a phosphate.

37. (Amended) The pharmaceutical composition according to claim 21, wherein the salt is an alkali metal halide.

38. (Amended) The pharmaceutical composition according to claim 21, wherein the salt is NaCl and/or KCl.

39. (Amended) The pharmaceutical composition according to claim 22, wherein the pH is adjusted using a phosphate buffer, tris buffer, HEPES buffer or MOPS buffer.

40. (Amended) The pharmaceutical composition according to claim 25, wherein about 25 to 35 amino acids are deleted from the L1 protein.

41. (Amended) The pharmaceutical composition according to claim 25, wherein about 32 to 34 amino acids are deleted from the L1 protein.

46. (Amended) The pharmaceutical composition according to claim 16, wherein the tumour is a carcinoma of the larynx, cervix, penis, vulva or anus and the L1 protein is a deleted L1 protein.

47. (Amended) The pharmaceutical composition according to claim 16, wherein the pharmaceutical composition contains no adjuvant and the L1 protein is a deleted L1 protein.

48. (Amended) The pharmaceutical composition according to claim 19, wherein the additive or excipient is about 0.3 to about 4 M of a salt having a pH of about 7.3 to about 7.45 and the L1 protein is a deleted L1 protein.

49. (Amended) The pharmaceutical composition according to claim 20, wherein the salt is an alkali metal or alkaline earth metal salt and the L1 protein is a deleted L1 protein.

50. (Amended) The pharmaceutical composition according to claim 20, wherein the pH is adjusted using a buffer and the L1 protein is a deleted L1 protein

51. (Amended) The pharmaceutical composition according to claim 30 in the form of a combination vaccine, wherein the papillomaviruses are selected from HPV-16 and HPV-18 or HPV-18, HPV-31, HPV-45 and HPV-58 or HPV-6 and HPV-11 and the L1 protein is a deleted L1 protein.

Sub-D⁴ 52. (Amended) The pharmaceutical composition according to claim 16, wherein the tumour is a carcinoma of the larynx, cervix, penis, vulva or anus.

53. (Amended) The pharmaceutical composition according to claim 16, wherein the pharmaceutical composition contains no adjuvant.

03 54. (Amended) The pharmaceutical composition according to claim 19, wherein the additive or excipient is about 0.3 to about 4 M of a salt having a pH of about 7.3 to about 7.45.

55. (Amended) The pharmaceutical composition according to claim 20, wherein the salt is an alkali metal or alkaline earth metal salt.

56. (Amended) The pharmaceutical composition according to claim 20, wherein the pH is adjusted using a buffer.

57. (Amended) The pharmaceutical composition according to claim 30 in the form of a combination vaccine, wherein the papillomaviruses are selected from HPV-16 and HPV-18 or HPV-18, HPV-31, HPV-45 and HPV-58 or HPV-6 and HPV-11.

04 Please add the following new claims 58-61:

58. (New) The pharmaceutical composition according to claim 30 or 51, wherein the HPV is selected from HPV-6, HPV-11, HPV-16, HPV-31, HPV-33, HPV-35, HPV-42, HPV-52, and/or HPV-58.

59. (New) The pharmaceutical composition according to claim 58, wherein the HPV is HPV-16.